Mereo BioPharma Group plc Cash Flow Conversion Efficiency
Mereo BioPharma Group plc cash flow conversion efficiency. Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has a cash flow conversion efficiency ratio of -0.188x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.68 Million ≈ $-8.98 Million USD) by net assets (€40.92 Million ≈ $47.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mereo BioPharma Group plc (2016–2025)
Cash flow conversion efficiency of Mereo BioPharma Group plc from 2016 to 2025. This chart illustrates how Mereo BioPharma Group plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Mereo BioPharma Group plc stock quote for real-time trading data and today's change.
Mereo BioPharma Group plc Cash Flow Conversion Ratio Explained
Mereo BioPharma Group plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mereo BioPharma Group plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mereo BioPharma Group plc ranked by their cash flow conversion efficiency. Also see market cap of Mereo BioPharma Group plc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Poulaillon SA
PA:ALPOU
|
0.198x |
|
Ironbark Capital Ltd
AU:IBC
|
0.031x |
|
Datron AG
XETRA:DAR
|
0.117x |
|
Jeil Technos Co.Ltd
KQ:038010
|
0.128x |
|
Chow Steel Industries Public Company Limited
BK:CHOW
|
0.041x |
|
Bowim S.A.
WAR:BOW
|
0.090x |
|
TDb Split Corp
TO:XTD
|
-0.045x |
|
Hitech Group Australia Ltd
AU:HIT
|
0.234x |
Annual Cash Flow Conversion Efficiency for Mereo BioPharma Group plc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Mereo BioPharma Group plc from 2016 to 2025. Review Mereo BioPharma Group plc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €40.92 Million ≈ $47.84 Million |
€-30.97 Million ≈ $-36.21 Million |
-0.757x | -40.56% |
| 2024-12-31 | €60.97 Million ≈ $71.28 Million |
€-32.83 Million ≈ $-38.39 Million |
-0.539x | -28.79% |
| 2023-12-31 | €50.54 Million ≈ $59.08 Million |
€-21.13 Million ≈ $-24.71 Million |
-0.418x | +33.36% |
| 2022-12-31 | €61.87 Million ≈ $72.33 Million |
€-38.82 Million ≈ $-45.38 Million |
-0.627x | -953.98% |
| 2021-12-31 | €88.00 Million ≈ $102.88 Million |
€-5.24 Million ≈ $-6.12 Million |
-0.060x | -103.14% |
| 2020-12-31 | €-14.97 Million ≈ $-17.50 Million |
€-28.34 Million ≈ $-33.13 Million |
1.893x | +265.92% |
| 2019-12-31 | €40.26 Million ≈ $47.06 Million |
€-45.93 Million ≈ $-53.70 Million |
-1.141x | -61.59% |
| 2018-12-31 | €32.77 Million ≈ $38.31 Million |
€-23.14 Million ≈ $-27.05 Million |
-0.706x | -37.23% |
| 2017-12-31 | €62.48 Million ≈ $73.05 Million |
€-32.15 Million ≈ $-37.59 Million |
-0.515x | -37.48% |
| 2016-12-31 | €79.26 Million ≈ $92.66 Million |
€-29.66 Million ≈ $-34.68 Million |
-0.374x | -- |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung dise… Read more